Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Nivolumab in Relapsed/Refractory PCNSL or PTL
2016-000894-19Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in primary central nervous system lymphoma (PCNSL) and testicular lymphoma (PTL), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate by blinded independent central review (primary). Started Aug 2016; status: completed.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)testicular lymphoma (PTL)
Beyond the preview
Go deeper on 2016-000894-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000894-19.